Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug
Gelteq (NASDAQ: GELS) has received FDA approval for its suitability petition for a new animal drug development, marking its entry into the animal pharmaceuticals market. The approval enables a fast-track pathway through an abbreviated new animal drug application (ANADA) for converting an existing FDA-approved generic animal drug from pill form to an oral gel form using Gelteq's ingestible gel platform.
The FDA's approval under section 512(n)(3)(C) of the FD&C Act eliminates the need for additional safety and effectiveness studies, potentially reducing the timeframe for final drug approval. However, the company notes that this suitability petition approval does not guarantee final ANADA approval for the proposed generic new animal drug.
Gelteq (NASDAQ: GELS) ha ricevuto l'approvazione dalla FDA per la sua petizione di idoneità per lo sviluppo di un nuovo farmaco animale, segnando il suo ingresso nel mercato dei farmaci veterinari. L'approvazione consente un percorso accelerato attraverso una domanda abbreviata per un nuovo farmaco animale (ANADA) per convertire un farmaco animale generico già approvato dalla FDA da forma di pillola a forma di gel orale utilizzando la piattaforma di gel ingeribile di Gelteq.
L'approvazione della FDA ai sensi della sezione 512(n)(3)(C) della FD&C Act elimina la necessità di ulteriori studi di sicurezza ed efficacia, riducendo potenzialmente i tempi per l'approvazione finale del farmaco. Tuttavia, l'azienda sottolinea che l'approvazione di questa petizione di idoneità non garantisce l'approvazione finale dell'ANADA per il nuovo farmaco animale generico proposto.
Gelteq (NASDAQ: GELS) ha recibido la aprobación de la FDA para su petición de idoneidad para el desarrollo de un nuevo medicamento animal, marcando su entrada en el mercado de fármacos veterinarios. La aprobación permite una vía acelerada a través de una solicitud abreviada para un nuevo medicamento animal (ANADA) para convertir un medicamento genérico animal ya aprobado por la FDA de forma de píldora a forma de gel oral utilizando la plataforma de gel ingerible de Gelteq.
La aprobación de la FDA según la sección 512(n)(3)(C) de la FD&C Act elimina la necesidad de estudios adicionales de seguridad y efectividad, lo que puede reducir el tiempo para la aprobación final del medicamento. Sin embargo, la compañía señala que esta aprobación de la petición de idoneidad no garantiza la aprobación final del ANADA para el nuevo medicamento animal genérico propuesto.
겔테크 (NASDAQ: GELS)는 새로운 동물 의약품 개발을 위한 적합성 청원에 대해 FDA의 승인을 받았으며, 이를 통해 동물 의약품 시장에 진입하게 되었습니다. 이 승인은 겔테크의 섭취 가능한 젤 플랫폼을 사용하여 기존 FDA 승인_GENERIC 동물 의약품을 알약에서 경구 젤 형태로 전환하는 빠른 경로를 제공합니다.
FD&C 법의 512(n)(3)(C) 항목에 따른 FDA의 승인은 추가적인 안전성 및 유효성 연구의 필요성을 없애고, 최종 의약품 승인에 대한 시간을 단축시킬 수 있습니다. 그러나 회사는 이 적합성 청원 승인이 제안된 새로운 동물 의약품의 최종 ANADA 승인을 보장하지는 않는다고 밝혔습니다.
Gelteq (NASDAQ: GELS) a reçu l'approbation de la FDA pour sa demande d'adéquation concernant le développement d'un nouveau médicament pour animaux, marquant ainsi son entrée sur le marché des médicaments vétérinaires. Cette approbation permet une voie accélérée grâce à une demande abrégée pour un nouveau médicament animal (ANADA) afin de convertir un médicament animal générique déjà approuvé par la FDA de la forme de pilule à celle de gel oral en utilisant la plateforme de gel ingérable de Gelteq.
L'approbation de la FDA en vertu de la section 512(n)(3)(C) de la loi FD&C élimine le besoin d'études supplémentaires sur la sécurité et l'efficacité, ce qui pourrait réduire le délai d'approbation finale du médicament. Cependant, la société souligne que cette approbation de la demande d'adéquation ne garantit pas l'approbation finale de l'ANADA pour le nouveau médicament animal générique proposé.
Gelteq (NASDAQ: GELS) hat die FDA-Zulassung für seinen Antrag auf Eignung für die Entwicklung eines neuen Tierarzneimittels erhalten, was den Einstieg in den Tierpharmazeutischen Markt markiert. Die Zulassung ermöglicht einen beschleunigten Prozess durch einen abgekürzten Antrag für ein neues Tierarzneimittel (ANADA), um ein bereits von der FDA genehmigtes generisches Tierarzneimittel von Tablettenform in eine orale Gel-Form mit Hilfe der verzehrbaren Gel-Plattform von Gelteq umzuwandeln.
Die FDA-Zulassung gemäß Abschnitt 512(n)(3)(C) des FD&C-Gesetzes beseitigt die Notwendigkeit weiterer Sicherheits- und Wirksamkeitsstudien, was den Zeitrahmen für die endgültige Arzneimittelzulassung potenziell verkürzt. Das Unternehmen weist jedoch darauf hin, dass diese Eignungsantrag-Zulassung keine Garantie für die endgültige ANADA-Zulassung des vorgeschlagenen generischen neuen Tierarzneimittels darstellt.
- FDA approval of suitability petition enables fast-track pathway for animal drug development
- No additional safety and effectiveness studies required, reducing development costs and timeline
- Strategic entry into the animal pharmaceuticals market
- Suitability petition approval does not guarantee final ANADA approval
- Company still needs to complete ANADA process before commercialization
Insights
The FDA's approval of Gelteq's suitability petition marks a significant regulatory milestone. The approval under section 512(n)(3)(C) of the FD&C Act is particularly noteworthy as it eliminates the need for additional safety and effectiveness studies, potentially reducing development costs and time to market by months or years. Converting the reference drug from pill to gel form through the ANADA pathway represents a strategic regulatory approach, as it leverages existing safety data while introducing an innovative delivery method. However, investors should note that while this fast-track designation is promising, it doesn't guarantee final ANADA approval.
This development positions Gelteq strategically in the growing animal pharmaceuticals market. The global animal drug market, valued at
Approval grants Gelteq fast track pathway for drug and entrance into the animal pharmaceuticals space
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and biotechnology company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports, and other products, announces today that the U.S. Food and Drug Administration (“FDA”) has approved its suitability petition for a new animal drug under development. The new animal drug leverages Gelteq’s ingestible gel platform designed for nutrient and drug delivery. A suitability petition is a request by a drug sponsor to submit an abbreviated new animal drug application (“ANADA”) for a proposed innovative new animal drug that differs from a previously FDA approved generic animal drug.
“We believe there is enormous opportunity for us in the animal pharmaceuticals market, as there is a significant need to deliver medications more efficiently,” Gelteq co-founder and CEO Nathan Givoni said. “This pathway, which is essentially a faster track as opposed to the standard new animal drug application (NADA) pathway, is a strategic way for us to expedite our entry into the animal drug space and provide long-term value for all our stakeholders.”
Gelteq has proposed changing the reference drug from a pill form into an oral gel form. These changes could be considered through the suitability petition, as defined under section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (the “FD&C Act”). The FDA found that the proposed changes did not require Gelteq to conduct further investigations to show the safety and effectiveness of the innovative new animal drug for its intended uses. Therefore, the FDA approved the petition under section 512(n)(3)(C) of the FD&C Act which foregoes the safety and effectiveness studies and helps reduce the timeframe to reach potential approval of the new animal drug. This approval of the suitability petition, however, does not guarantee approval of the ANADA for Gelteq’s proposed generic new animal drug.
About Gelteq Limited:
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and biotechnology company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in the Annual Report on 20-F filed on November 15, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.
Contact:
CORE IR
516-222-2560
pr@gelteq.com
FAQ
What does Gelteq's FDA suitability petition approval mean for GELS stock?
How will Gelteq (GELS) modify the existing animal drug?
What regulatory requirements did the FDA waive for Gelteq's (GELS) animal drug?
What is the market opportunity for Gelteq's (GELS) new animal drug?
